###begin article-title 0
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Aims
###end title 2
###begin p 3
###xml 211 213 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 362 364 362 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
The aldose reductase (AR) gene, a rate-limiting enzyme of the polyol pathway, has been investigated as a candidate gene in determining susceptibility to diabetic microangiopathy. However, the association of the AR gene with diabetic macroangiopathy has not been investigated. Therefore, the present study was conducted to determine whether genetic variations of AR may determine susceptibility to diabetic macroangiopathy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 31 39 <span type="species:ncbi:9606">patients</span>
There were 378 Type 2 diabetic patients enrolled in this study. A single nucleotide polymorphism in the promoter region (C-106T) was genotyped and the AR protein content of erythrocytes measured by ELISA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 495 497 495 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 631 633 631 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
There were no significant differences in genotypic or allelic distribution in patients with or without ischaemic heart diseases, but there was a significant increase in the frequency of the CT + TT genotype and T allele in patients with stroke (P = 0.019 and P = 0.012). The erythrocyte AR protein content was increased in patients with the CT and TT genotype compared with those with the CC genotype. After adjustment for age, duration of diabetes, body mass index, systolic blood pressure, HbA1c, and serum creatinine, triglycerides, and total cholesterol in multivariate logistic-regression models, the association between this AR genotype and stroke remained significant.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 54 56 54 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
Our results suggest that the CT or TT genotype of the AR gene might be a genetic marker of susceptibility to stroke in Type 2 diabetic patients. This observation might contribute to the development of strategies for the prevention of stroke in Type 2 diabetic patients.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 511 513 511 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 626 627 626 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 871 872 871 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
There is familial clustering in the incidence of diabetes-related chronic complications [1], which suggests the existence of genetic susceptibility to these complications. Many studies have indicated that overactivity of the polyol pathway contributes to the development of diabetic microvascular complications by demonstrating the preventive effects of polyol pathway inhibition on these complications [2]. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway, and thus polymorphisms in the AR gene may be one of the factors that determine genetic susceptibility to diabetic microvascular complications [3,4]. Recently, a new polymorphism, C-106T, at position -106 in the promoter region of AR, was identified and an association with diabetic microangiopathy in Caucasian and Asian subjects with Type 1 and Type 2 diabetes mellitus has been reported [5-12].
###end p 11
###begin p 12
###xml 115 122 115 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 134 142 134 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 163 165 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 268 270 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
Other reports have indicated a role of polyol pathway hyperactivity in the development of diabetic macroangiopathy in vivo[13,14] and in vitro[3,15,16]. Thus, the AR gene could also be a predisposing factor to diabetic macroangiopathy. However, the association of the AR gene with macroangiopathy in diabetic subjects has never been reported.
###end p 12
###begin p 13
###xml 95 97 95 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
To clarify these issues, the present study investigated whether the C-106T polymorphism of the AR gene determines susceptibility to diabetic macroangiopathy, such as ischaemic heart disease and cerebrovascular disease, in Japanese Type 2 diabetic patients and non-diabetic subjects.
###end p 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 14
###begin p 15
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 75 83 <span type="species:ncbi:9606">Patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 342 345 <span type="species:ncbi:9606">men</span>
###xml 354 359 <span type="species:ncbi:9606">women</span>
###xml 438 441 <span type="species:ncbi:9606">men</span>
###xml 450 455 <span type="species:ncbi:9606">women</span>
We screened 417 consecutive patients attending Nagoya University Hospital. Patients with Type 1 diabetes (14), malignant diseases (13) and other types of diabetes (steroid or pancreatectomy induced; 10) were excluded. During screening, two patients declined to participate. A total of 378 Type 2 diabetic outpatients (28-88 years of age, 210 men and 168 women) were enrolled. A total of 334 non-diabetic subjects (17-89 years of age, 206 men and 128 women) who underwent a medical check-up in our hospital from April 2001 to December 2003 served as the control group. They had fasting blood glucose levels < 6.1 mmol/l and had no family history of diabetes. Five had an abnormal electrocardiogram and 20 a history of atherosclerotic diseases.
###end p 15
###begin p 16
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
Assessment and definition of diabetic macroangiopathy was based on the following criteria. Cardiovascular disease was defined by a history of ischaemic cardiovascular diseases (e.g. previous myocardial infarction, angina, coronary-artery bypass grafting). Stroke (ischaemic cerebrovascular disease) was diagnosed by means of neurological signs and symptoms, together with computed tomography or magnetic resonance imaging. According to the Acute Stroke Treatment (TOAST) classification [17], only large-vessel diseases and carotid stroke were enrolled, and cardioembolic and lacunar stroke were excluded. Data regarding the presence of peripheral vascular disease (PVD) were also collected but the prevalence was too low to conduct statistical analyses, and is not included in this paper. The study protocol and informed consent procedure were approved by the Ethics Committee of Nagoya University Hospital and was performed in accordance with the Helsinki Declaration of 1975, as revised in 1983.
###end p 16
###begin title 17
Genotyping
###end title 17
###begin p 18
###xml 139 141 139 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bfa-I</italic>
###xml 508 513 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bfa-I</italic>
###xml 657 662 <span type="species:ncbi:9606">human</span>
DNA samples were prepared from whole blood using a QIAamp DNA Blood Mini Kit (Qiagen, Chatsworth, CA, USA). The C-106T polymorphism of the AR gene was determined by the polymerase chain reaction restriction fragment length polymorphism method using the primers and conditions described by Kao et al. [5]. The presence of the C allele was indicated by a 206-bp fragment and T allele was indicated by 147- and 59-bp fragments after overnight digestion with Bfa-I at 37degreesC. Before enzymatic digestion with Bfa-I, the product was purified with QIAquick PCR Purification Kit (Qiagen). The AR protein content in erythrocytes was measured by ELISA using anti-human AR monoclonal antibody (Mitsubishi Gas Chemical, Tokyo, Japan).
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 130 132 128 130 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sd</sc>
###xml 258 259 254 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 287 288 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 298 303 294 299 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anova</sc>
###xml 399 400 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 638 639 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Statistical analyses were performed using SPSS for Windows version 12.0 (SPSS, Chicago, IL, USA). Data are presented as means +/- sd, unless otherwise indicated. Statistical significance of the differences between the groups was determined by chi-square (chi2) tests, unpaired Student's t-tests or anova where appropriate. The Hardy-Weinberg test was performed using a standard observed-expected chi2 test. Multiple logistic-regression analyses were used to assess the association of the CT + TT genotype with diabetic complications. Odds ratios (ORs) and their confidence intervals (CIs) were used to estimate relative risk. A two-sided P-value less than 0.05 was considered statistically significant.
###end p 20
###begin title 21
Results
###end title 21
###begin p 22
###xml 93 100 93 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of diabetic patients and non-diabetic subjects are presented in Table 1. The mean age, body mass index (BMI), fasting blood glucose levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), and serum levels of triglycerides and creatinine of diabetic patients were higher than those of non-diabetic subjects. The high-density lipoprotein (HDL) cholesterol of diabetic patients was lower than that of non-diabetic subjects.
###end p 22
###begin p 23
Clinical characteristics of the study population
###end p 23
###begin p 24
###xml 23 25 21 23 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sd</sc>
Data are n or mean +/- sd.
###end p 24
###begin p 25
D, diet only; O, oral glucose-lowering agents; I, insulin; I+O, insulin and oral glucose-lowering agents.
###end p 25
###begin p 26
###xml 57 59 57 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 486 487 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 509 510 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 530 531 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 551 552 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The genotype distributions of the C-106T polymorphism of AR gene were 259 (68.5%) for CC, 105 (27.8%) for CT, and 14 (3.7%) for TT in the diabetic group, and 213 (63.8%) for CC, 113 (33.8%) for CT, and 8 (2.4%) for TT in the non-diabetic group. The frequencies of the C allele were 82.6% in the diabetic group and 80.7% in the non-diabetic group. The distribution of genotypes was in Hardy-Weinberg equilibrium. There were no significant differences between the two groups (genotype chi2 = 3.708 with 2 d.f., P = 0.157; allele chi2 = 0.698 with 1 df, P = 0.404).
###end p 26
###begin p 27
###xml 252 254 252 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Because the number of diabetic patients with the TT genotype was only 3.7%, subjects with the CT and TT genotypes were combined for further analyses. The genotypes were not associated with gender, duration of diabetes, age, diabetes treatment, BMI, HbA1c and fasting blood glucose levels, SBP, DBP, serum levels of total cholesterol, triglycerides, HDL cholesterol, low-density lipoprotein (LDL) cholesterol and creatinine.
###end p 27
###begin p 28
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
Table 2 shows the distribution of the C-106T polymorphism in diabetic patients with or without ischaemic heart disease or stroke. Stroke was more frequent in patients with the CT and TT genotypes and T allele than those with the CC genotype and C allele. However, there were no significant differences in the prevalence of ischaemic heart disease between genotypes or alleles.
###end p 28
###begin p 29
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Relationship between the AR genotype, allele and diabetic macroangiopathy in Japanese Type 2 diabetic patients
###end p 29
###begin p 30
Data are % (n).
###end p 30
###begin p 31
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 16 17 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
P, two-sided chi2 test.
###end p 31
###begin p 32
###xml 233 234 227 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 261 267 255 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
We then compared the AR protein content in erythrocytes among the genotypes. The AR content was significantly increased in a genotype-dependent manner (CC, 11.2 +/- 2.5 ng/mg Hb; CT, 12.2 +/- 2.8 ng/mg Hb; TT, 13.9 +/- 2.9 ng/mg Hb, P = 0.002 and 0.001 vs. CC; Fig. 1). However, there was no relationship between AR content and presence of macroangiopathy.
###end p 32
###begin p 33
###xml 124 126 122 124 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sd</sc>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Erythrocyte AR contents of diabetic patients classified according to genotype of the C-106T polymorphism. Data are mean +/- sd.
###end p 33
###begin p 34
###xml 5 6 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
Age (P = 0.003), SBP (P < 0.001), serum creatinine levels (P = 0.008) and serum levels of triglycerides (P = 0.048) were higher in patients with a history of stroke.
###end p 34
###begin p 35
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 410 412 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Table 3 shows the results of multivariate logistic-regression analyses with two models. After adjustment for age, SBP and serum levels of creatinine and triglycerides in model 1, individuals with the CT and TT genotypes were significantly more likely to have had a stroke than individuals with the CC genotype (OR 2.40, 95% CI 1.15-5.01, P = 0.019). Furthermore, in model 2, after additional adjustment for HbA1c, BMI, serum total-cholesterol levels and duration of diabetes, this relationship remained (OR 2.79, 95% CI 1.27-6.13, P = 0.010).
###end p 35
###begin p 36
Odds ratios for associations between risk factors and the prevalence of stroke with the use of multivariate logistic-regression models
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 75 77 75 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
We have investigated the C-106T polymorphism in the promoter region of the AR gene as a candidate gene for susceptibility to diabetic macroangiopathy, and found that the CT or TT genotype is associated with increased risk of stroke in Type 2 diabetic patients.
###end p 38
###begin p 39
###xml 170 178 <span type="species:ncbi:9606">patients</span>
Diabetes mellitus is one of the major risk factors of coronary heart disease and cerebrovascular disease. The high prevalence of these macrovascular diseases in diabetic patients can be explained by hyperglycaemia per se, as well as by the increased frequency of conventional risk factors such as hypertension, dyslipidaemia, and obesity.
###end p 39
###begin p 40
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 474 476 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 812 814 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1203 1204 1199 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 667 670 <span type="species:ncbi:9615">dog</span>
Accelerated proliferation of vascular smooth muscle cells (SMCs) is one of the characteristic features of atherosclerosis [18], and it has been proposed that hyperglycaemia contributes to the hyperproliferation of SMCs [15,19]. Moreover, there are some reports that the inhibition of the polyol pathway by AR inhibitors prevents the enhanced proliferation of SMCs cultured in high-glucose conditions [15,16,20] and also prevents hyperglycaemia-induced NF-kappaB activation [21] which is involved in inflammatory signal transduction. We have previously shown that hyperactivity of the polyol pathway caused intimal thickening of coronary arteries in the galactose-fed dog, an animal model of polyol pathway hyperactivity, and that this abnormality was ameliorated by treatment with an aldose reductase inhibitor [13]. Taken together, these results indicate that polyol pathway hyperactivity may be involved in the hyperplasia of SMCs, and may play a substantial role in the development of diabetic macroangiopathy. However, previous studies have demonstrated that polyol pathway hyperactivity contributes to the development of diabetic microangiopathy, including neuropathy, nephropathy and retinopathy [2].
###end p 40
###begin p 41
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 19 21 19 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 229 231 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 624 626 624 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 692 697 692 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
Hodgkinson et al. [22] reported that there is a significant correlation between increased AR expression, antioxidant gene mRNA levels in peripheral mononuclear cells cultured in high glucose and the CA repeat polymorphism of the AR gene in patients with nephropathy. Furthermore, the CT or TT genotypes and the T allele of this polymorphism have been identified as genetic markers of susceptibility to diabetic microangiopathy in several reports [5-12]. Therefore, genetic susceptibility to the development of not only microvascular but also macrovascular diseases in diabetes may be explained by the C-106T polymorphism of AR gene. However, a functional reporter gene assay reported by Yang et al. [23] showed that the promoter activity of a construct containing the C allele is higher than of a construct with the T allele in transfected HepG2 cells in high-glucose conditions. Further studies will be required to clarify these inconsistent results.
###end p 41
###begin p 42
###xml 90 92 90 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 465 467 465 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
We showed that the CT and TT genotypes and the T allele of the C-106T polymorphism in the AR promoter region are thought to be a risk factor for stroke. Some independent effects of genetic variants (e.g. prothrombin gene, factor V gene, methylenetetrahydrofolate reductase gene, apolipoprotein gene) on the risk of cerebral ischaemia have been reported previously [24]. Compared with these gene variants, the adjusted OR we observed in this study suggests that the AR gene exerts a stronger effect on the risk of stroke.
###end p 42
###begin p 43
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 102 104 102 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 395 397 395 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
Makiishi et al. reported, for the first time, the relationship between the C-106T polymorphism of the AR gene and erythrocyte AR content in Type 2 diabetic subjects [9]. The results obtained in this study that AR contents were increased in a genotype-dependent fashion (CC < CT < TT), are not completely consistent with their observation, but do support the hypothesis that polymorphisms of the AR gene influence erythrocyte AR content and the development of diabetic complications. Unfortunately, however, a significant relationship between the AR content in erythrocytes and the prevalence of stroke was not observed in our study.
###end p 43
###begin p 44
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
Our findings should be cautiously interpreted because there are some limitations to the present study. Our analysis of the AR gene was limited to a single marker from the 5' region of the gene. Thus, it cannot be excluded that this AR polymorphism is in linkage disequilibrium with an unidentified polymorphism strongly related to stroke risk. This could explain the lack of correlation between AR content in erythrocytes and the prevalence of stroke. Hyperglycaemia, hyperosmolality, and oxidative stress all regulate erthrocyte AR content [25-28], and also contribute to the development of diabetic complications including macroangiopathy. Therefore, the strength of the influence of these factors on erythrocyte AR content may explain our unexpected results
###end p 44
###begin p 45
###xml 550 552 550 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 855 857 855 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 1113 1115 1113 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
There are several well-known conventional risk factors for macrovascular diseases (for example, dyslipidaemia, hypertension, hyperglycaemia, and increasing age) but little is known about inherited factors that could predispose to diabetic macroangiopathy. Among the conventional risk factors, in the present study, age and systolic blood pressure were higher in the subjects with stroke than those without stroke, although the significance was weak after adjustment for various risk factors. In contrast, the CT + TT genotype and the T allele of the AR gene were associated with an increased risk of stroke, and the significance of these genotypes remained high even after adjustment for other risk factors. In addition, the erythrocyte AR content was higher in the subjects with these genotypes. Therefore, it may be speculated that polymorphisms of the AR gene, concomitant with an increase in erythrocyte AR content, would increase vulnerability of brain arteries resulting in stroke. However, prospective intervention studies with aldose reductase inhibitors would be required to confirm the influence of the AR gene polymorphism and AR content on the development of stroke.
###end p 45
###begin p 46
###xml 513 515 513 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
In contrast, it is noteworthy that the influence of this polymorphism on the development of ischaemic heart disease is less than that on stroke. There are important differences in risk factors for stroke and ischaemic heart disease. For stroke, hypertension is the most adverse risk factor, whereas for ischaemic heart diseases LDL cholesterol is the strongest. This suggests that there are differences in the pathogenesis of ischaemic heart disease and stroke, which might explain our lack of association of the AR gene with ischaemic heart disease. It can be speculated that brain vessels are more sensitive to polyol pathway-induced hyperosmolar stress than coronary vessels. Precise investigation will be required to clarify this issue.
###end p 46
###begin p 47
###xml 152 154 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 284 286 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
It is important to replicate our results in other populations. No previous study has investigated the relationship between diabetic macroangiopathy and AR polymorphisms in other populations. Although various studies have reported the relationship between diabetic microangiopathy and AR polymorphisms [5-12], consistent results have not been obtained, which may be as a result of differences between racial groups. Further study would be required to clarify this issue.
###end p 47
###begin p 48
###xml 88 90 88 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AR</italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
In conclusion, we have found that the C-106T polymorphism in the promoter region of the AR gene is associated with an increased risk of stroke in Type 2 diabetic patients. This observation might contribute to the development of further strategies for the prevention of stroke in Type 2 diabetic patients.
###end p 48
###begin title 49
Competing interests
###end title 49
###begin p 50
None declared.
###end p 50
###begin p 51
We thank Dr Hiroshi Yatsuya for support in statistical analyses, and Kimiko Sato and Yuko Maehata for technical support.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus
###end article-title 53
###begin article-title 54
Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications
###end article-title 54
###begin article-title 55
Genetic analysis of aldose reductase in diabetic complications
###end article-title 55
###begin article-title 56
Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications
###end article-title 56
###begin article-title 57
A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes
###end article-title 57
###begin article-title 58
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus
###end article-title 58
###begin article-title 59
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus
###end article-title 59
###begin article-title 60
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes
###end article-title 60
###begin article-title 61
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus
###end article-title 61
###begin article-title 62
Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes
###end article-title 62
###begin article-title 63
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes
###end article-title 63
###begin article-title 64
###xml 118 126 <span type="species:ncbi:9606">patients</span>
C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control
###end article-title 64
###begin article-title 65
###xml 99 110 <span type="species:ncbi:9615">beagle dogs</span>
An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs
###end article-title 65
###begin article-title 66
Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells
###end article-title 66
###begin article-title 67
###xml 47 50 <span type="species:ncbi:10116">rat</span>
Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity
###end article-title 67
###begin article-title 68
###xml 147 150 <span type="species:ncbi:10116">rat</span>
Suppression of 3-deoxyglucosone and heparin-binding epidermal growth factor-like growth factor mRNA expression by an aldose reductase inhibitor in rat vascular smooth muscle cells
###end article-title 68
###begin article-title 69
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Studies of Org 10172 in patients with acute ischemic stroke
###end article-title 69
###begin article-title 70
The pathogenesis of atherosclerosis: a perspective for the 1990s
###end article-title 70
###begin article-title 71
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose
###end article-title 71
###begin article-title 72
###xml 102 105 <span type="species:ncbi:10116">rat</span>
An aldose reductase inhibitor prevents the glucose-induced increase in PDGF-beta receptor in cultured rat aortic smooth muscle cells
###end article-title 72
###begin article-title 73
Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase
###end article-title 73
###begin article-title 74
###xml 66 74 <span type="species:ncbi:9606">patients</span>
The response of antioxidant genes to hyperglycemia is abnormal in patients with type 1 diabetes and diabetic nephropathy
###end article-title 74
###begin article-title 75
Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications
###end article-title 75
###begin article-title 76
Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults
###end article-title 76
###begin article-title 77
###xml 53 58 <span type="species:ncbi:9606">human</span>
Altered aldose reductase gene regulation in cultured human retinal pigment epithelial cells
###end article-title 77
###begin article-title 78
###xml 82 87 <span type="species:ncbi:9606">human</span>
Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene
###end article-title 78
###begin article-title 79
###xml 56 61 <span type="species:ncbi:9606">human</span>
Characterization of the osmotic response element of the human aldose reductase gene promoter
###end article-title 79
###begin article-title 80
Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells
###end article-title 80
###begin title 81
Abbreviations
###end title 81
###begin p 82
aldose reductase
###end p 82
###begin p 83
body-mass index
###end p 83
###begin p 84
diastolic blood pressure
###end p 84
###begin p 85
high-density lipoprotein
###end p 85
###begin p 86
low-density lipoprotein
###end p 86
###begin p 87
systolic blood pressure
###end p 87
###begin p 88
smooth muscle cells
###end p 88

